Interpace Diagnostics to Present at The MicroCap Conference on October 5th in New York City at the Essex House

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that it will be presenting at this year’s MicroCap Conference on October 5th in New York City. For additional information on Interpace, please visit our website at www.interpacediagnostics.com or contact Paul Kuntz at 412-708-4590 or paul@redchip.com.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

The MicroCap Conference will take place in New York City at the Essex House on October 5th. Registration will begin on Thursday at 7:00AM, and will last until the evening. These days will be jam-packed with company sessions, presentations, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (microcapconf.com/conferences/new-york-2-2017/), and click “Investor Registration.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (microcapconf.com/conferences/new-york-2-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

OTHER SPONSORS

M2 Compliance
MZ Group
Pryor Cashman
Wexler Burkhart Hirschberg & Unger
IRTH Communications
PCG Advisory Group
CORE IR
Catalyst IR
Marcum

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com

SOURCE: Interpace Diagnostics Group, Inc.

ReleaseID: 476226